Back to Search Start Over

Outcome after treatment for sebaceous carcinoma: A multicenter study

Authors :
Eva Huis In 't Veld
Ronald Keizer
Nicoline Post
Jeroen Versteeg
Robert Verdijk
Nicole Naus
Germaine Relyveld
Marianne Crijns
Myles Smith
Dirk Grünhagen
Marlies Wakkee
Dion Paridaens
Ioannis Zavrakidis
Antien Mooyaart
Alexander van Akkooi
Dirk Strauss
Cornelis Verhoef
Michel Wouters
Andrew Hayes
Winan van Houdt
Pathology
Ophthalmology
Surgery
Dermatology
Source :
Journal of Surgical Oncology, 125(4), 730-735. Wiley-Liss Inc.
Publication Year :
2022
Publisher :
Wiley, 2022.

Abstract

BACKGROUND: Sebaceous carcinoma (SC) is a rare malignant tumour whereby, comprehensive long-term data are scarce. This study aimed to assess the outcome of patients treated with resection for SC.METHODS: Patients treated at four tertiary centres were included. Cumulative incidence curves were calculated for recurrences.RESULTS: A total of 100 patients (57 males, 57%) were included with 103 SCs. The median age was 72 (range, 15-95) years with a median follow-up of 52 (interquartile range [IQR], 24-93) months. Most SCs were located (peri)ocular (49.5%). Of all SCs, 17 locally recurred (16.5%) with a median time to recurrence of 19 (IQR, 8-29) months. The cumulative incidence probability for recurrence was statistically higher for (peri)ocular tumours (p = 0.005), and for positive resection margins (p = 0.001). Two patients presented with lymph node metastases and additional seven patients (8.7%) developed lymph node metastases during follow-up with a median time to metastases of 8 (IQR, 0.5-28) months. Three patients had concurrent in-transit metastases and one patient also developed liver and bone metastases during follow-up.CONCLUSION: SC is a rare, yet locally aggressive tumour. Positive resection margins and (peri)ocular SCs are more frequently associated with local recurrence. SC infrequently presents with locoregional or distant metastases.

Details

ISSN :
10969098 and 00224790
Volume :
125
Database :
OpenAIRE
Journal :
Journal of Surgical Oncology
Accession number :
edsair.doi.dedup.....85547a28fbe67fccc01a2b99e2609db8